NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Artrodar®50mg (diacerein): New restrictions of use to limit the risk of severe diarrhoea and effects on the liver

User Rating: 2 / 5

Star ActiveStar ActiveStar InactiveStar InactiveStar Inactive
 

Date: 12 February 2015

Description:

A Direct Healthcare Professional Communication (DHPC) has been approved by NPCB to inform healthcare professionals of the risk of severe diarrhoea and hepatotoxicity with the osteoarthritis medication, Artrodar® (diacerein). The use has been restricted to minimise these risks, including tightening of indication and recommending a lower starting dose.The package inserts for Artrodar® will be updated by TRB Chemedica Malaysia Sdn. Bhd.to reflect these safety changes. Please refer to the DHPC for further information.

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Thursday 10 October 2024, 14:54:22.

Search

Main Menu English